Arovella TherapeuticsASX:ALA +1.52% 3-Year ROIIC % is 161.24 as of Jun. 2025, which is 180% above its 10-year median of 57.52. The stock has 1 warning sign investors should review. Among 1,318 Biotechnology companies, Arovella Therapeutics ranks better than 82.4% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Arovella Therapeutics's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 161.24%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Arovella Therapeutics's 3-Year ROIIC % or its related term are showing as below:
ASX:ALA's 3-Year ROIIC % is ranked better than 82.4% of 1318
companies
in the Biotechnology industry
Industry Median: -4.63
vs ASX:ALA: 161.24
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Arovella Therapeutics 3-Year ROIIC % Related Terms
Arovella Therapeutics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Arovella Therapeutics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ALA vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Arovella Therapeutics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arovella Therapeutics 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arovella Therapeutics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Arovella Therapeutics's 3-Year ROIIC % falls into.
Arovella Therapeutics's 3-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -11.203 (Jun. 2025) - -7.596 (Jun. 2022) )
/
( 0.562 (Jun. 2025) - 2.799 (Jun. 2022) )
=
-3.607
/
-2.237
=
161.24%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Arovella Therapeutics (ASX:ALA) has a 3-Year ROIIC % of 161.24 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Arovella Therapeutics and its competitors. This is 180% above median its historical median of 57.52. According to the industry distribution chart, Arovella Therapeutics ranks #232 out of 1318 companies in the Biotechnology industry, placing it in the top 17.6%.
Is Arovella Therapeutics' 3-Year ROIIC % too high?
Arovella Therapeutics' current 3-Year ROIIC % of 161.24 is 180% above median its 10-year median of 57.52. Based on the distribution chart, Arovella Therapeutics ranks #232 out of 1318 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Arovella Therapeutics' 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arovella Therapeutics ranks #232 out of 1318 companies for 3-Year ROIIC %. This places Arovella Therapeutics in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Arovella Therapeutics and its competitors. Arovella Therapeutics's current 3-Year ROIIC % is 161.24, which is 180% above median its own 10-year median of 57.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arovella Therapeutics stock overvalued right now?
Arovella Therapeutics (ASX:ALA) has a current 3-Year ROIIC % of 161.24. The current 3-Year ROIIC % is 161.24, which is 180% above median its 10-year median of 57.52. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Arovella Therapeutics (ASX:ALA), the current 3-Year ROIIC % is 161.24 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ALA has been successfully added to your 